Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Randomized, Double-Blind Trial of Ferumoxytol Compared to Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia: Safety and Efficacy

Michael Auerbach, MD, William E Strauss, MD, Iain C. Macdougall, MD, Kristine Bernard, MPH, Robert F Kaper, MD, Glenn M Chertow, MD MPH, Zhu Li, PhD, Anton Trochanov, MD, Naomi V Dahl, PharmD, Julie Krop, MD

Blood (2017) 130 (Supplement 1): 3500.

https://doi.org/10.1182/blood.V130.Suppl_1.3500.3500

Published: 2017

Journal Articles

Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer

Saroj Vadhan-Raj, MD, Naomi V. Dahl, Pharm D, Kristine Bernard, MPH, Zhu Li, PhD, William Strauss, MD, F.A.C.C.

Blood (2014) 124 (21): 1352.

https://doi.org/10.1182/blood.V124.21.1352.1352

Published: 2014

Journal Articles

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, Pharm.D., Gloria Lau, MSc, Kristine Bernard, Zhu Li, PhD, Pallabi De, PhD, Lee F. Allen, MD, PhD, William Strauss, M.D., F.A.C.C.

Blood (2013) 122 (21): 2201.

https://doi.org/10.1182/blood.V122.21.2201.2201

Published: 2013

Journal Articles

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Saroj Vadhan Raj, Michael Cressman, David Ford, William Strauss, M.D., F.A.C.C., Gerri Poss, Kristine Bernard, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2098.

https://doi.org/10.1182/blood.V120.21.2098.2098

Published: 2012

Journal Articles

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

David Hetzel, Audrone Urboniene, Kristine Bernard, William Strauss, M.D., F.A.C.C., Michael Cressman, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2099.

https://doi.org/10.1182/blood.V120.21.2099.2099

Published: 2012

Journal Articles

Relationship Between Iron Indices and Iron Responsiveness Following IV Ferumoxytol or Oral Iron In Patients with CKD Not on Dialysis

John Adamson, MD, Zhu Li, PhD, Paul Miller, MS, Annamaria Kausz, MD, MS

Blood (2010) 116 (21): 5149.

https://doi.org/10.1182/blood.V116.21.5149.5149

Published: 2010

NARROW

Randomized, Double-Blind Trial of Ferumoxytol Compared to Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia: Safety and Efficacy

Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

Relationship Between Iron Indices and Iron Responsiveness Following IV Ferumoxytol or Oral Iron In Patients with CKD Not on Dialysis

Email alerts

ASH Publications

American Society of Hematology

Randomized, Double-Blind Trial of Ferumoxytol Compared to Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia: Safety and Efficacy

Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Potential New Treatment Option for Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy- Results of a Phase III, Randomized, Open-Label, Active-Controlled Trial of Ferumoxytol.

Relationship Between Iron Indices and Iron Responsiveness Following IV Ferumoxytol or Oral Iron In Patients with CKD Not on Dialysis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only